Effect of Coenzyme Q10 Supplementation in Statin-Treated Obese Rats.

Hye-Kyung Choi, Eun-Kyung Won, Se-Young Choung
Author Information
  1. Hye-Kyung Choi: Department of Preventive Pharmacy and Toxicology, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea.
  2. Eun-Kyung Won: Department of Preventive Pharmacy and Toxicology, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea.
  3. Se-Young Choung: Department of Preventive Pharmacy and Toxicology, College of Pharmacy, Kyung Hee University, Seoul 02447, Republic of Korea.

Abstract

Statins, HMG-CoA reductase inhibitors, are known to cause serious muscle injuries (e.g. myopathy, myositis and rhabdomyolysis), and these adverse effects can be rescued by co-administration of coenzyme Q10 (CoQ10) with statins. The goal of the current research is to assess the efficacy of combined treatment of CoQ10 with Atorvastatin for hyperlipidemia induced by high-fat diet in SD rats. 4-week-old Sprague-Dawley male rats were fed normal diet or high-fat diet for 6 weeks. Then, rats were treated with either Statin or Statin with various dosages of CoQ10 (30, 90 or 270 mg/kg/day, p.o.) for another 6 weeks. Compared to Statin onlytreatment, CoQ10 supplementation significantlyreduced creatine kinase and aspartate aminotransferase levels in serum which are markers for myopathy. Moreover, CoQ10 supplementation with Statin further reduced total fat, triglycerides, total cholesterol, and low-density lipoprotein-cholesterol. In contrast, the levels of high-density lipoprotein-cholesterol and CoQ10 were increased in the CoQ10 co-treated group. These results indicate that CoQ10 treatment not only reduces the side effects of Statin, but also has an anti-obesity effect. Therefore an intake of supplementary CoQ10 is helpful for solving problem of obese metabolism, so the multiple prescription of CoQ10 makes us think a possibility that can be solved in being contiguous to the obesity problem, a sort of disease of the obese metabolism.

Keywords

References

  1. Biosci Rep. 2007 Jun;27(1-3):53-67 [PMID: 17492503]
  2. Neurochem Res. 2007 Apr-May;32(4-5):723-7 [PMID: 17094036]
  3. Invest New Drugs. 2001;19(1):81-3 [PMID: 11291836]
  4. Mitochondrion. 2007 Jun;7 Suppl:S168-74 [PMID: 17482884]
  5. Hypertension. 2002 Aug;40(2):142-7 [PMID: 12154104]
  6. Clin Cancer Res. 1996 Mar;2(3):483-91 [PMID: 9816194]
  7. Drug Saf. 2006;29(8):703-12 [PMID: 16872244]
  8. J Cell Mol Med. 2001 Oct-Dec;5(4):378-87 [PMID: 12067471]
  9. Crit Care. 2005 Apr;9(2):158-69 [PMID: 15774072]
  10. Am J Cardiol. 2007 May 15;99(10):1409-12 [PMID: 17493470]
  11. Clin Ther. 2006 Jan;28(1):26-35 [PMID: 16490577]
  12. J Cardiovasc Pharmacol. 2000 Feb;35(2):256-62 [PMID: 10672858]
  13. Toxicol Appl Pharmacol. 1998 Sep;152(1):99-106 [PMID: 9772205]
  14. Clin Chem. 1990 Dec;36(12):2145-7 [PMID: 2253372]
  15. Ochsner J. 2010 Spring;10(1):16-21 [PMID: 21603349]
  16. Proc Natl Acad Sci U S A. 1980 Jul;77(7):3957-61 [PMID: 6933445]
  17. Emerg Infect Dis. 2000 Mar-Apr;6(2):192-5 [PMID: 10756156]
  18. J Natl Med Assoc. 2009 Jul;101(7):705-10 [PMID: 19634592]
  19. N Engl J Med. 2009 Jul 2;361(1):62-72 [PMID: 19571284]
  20. Arch Neurol. 2004 Jun;61(6):889-92 [PMID: 15210526]
  21. Biochim Biophys Acta. 1994 Jul 6;1200(2):100-8 [PMID: 8031828]
  22. Cardiovasc Drugs Ther. 2003 Sep-Nov;17(5-6):459-65 [PMID: 15107601]
  23. Mol Biotechnol. 2007 Sep;37(1):31-7 [PMID: 17914161]
  24. Biofactors. 2003;18(1-4):185-93 [PMID: 14695934]
  25. Science. 2001 May 11;292(5519):1160-4 [PMID: 11349148]
  26. J Am Coll Nutr. 2001 Dec;20(6):591-8 [PMID: 11771674]
  27. J Am Coll Cardiol. 2007 Jun 12;49(23):2231-7 [PMID: 17560286]
  28. J Am Soc Nephrol. 2000 Aug;11(8):1553-61 [PMID: 10906171]
  29. Clin Pharmacol Ther. 1995 Jan;57(1):62-6 [PMID: 7828383]
  30. Eur J Clin Invest. 1994 Mar;24(3):173-8 [PMID: 8033951]
  31. J Nutr. 1993 Nov;123(11):1939-51 [PMID: 8229312]
  32. JAMA. 2003 Apr 2;289(13):1681-90 [PMID: 12672737]
  33. Am Fam Physician. 2005 Mar 15;71(6):1105-10 [PMID: 15791889]
  34. Vasc Med. 2003 Nov;8(4):289-90 [PMID: 15125495]
  35. Am J Cardiovasc Drugs. 2008;8(6):373-418 [PMID: 19159124]
  36. Arch Intern Med. 2010 Jun 28;170(12):1024-31 [PMID: 20585067]

Word Cloud

Created with Highcharts 10.0.0CoQ10StatinQ10dietratsStatinsHMG-CoAreductasemyopathyeffectscantreatmenthigh-fat6weekssupplementationlevelstotallipoprotein-cholesterolproblemobesemetabolismCoenzymeinhibitorsknowncauseseriousmuscleinjuriesegmyositisrhabdomyolysisadverserescuedco-administrationcoenzymestatinsgoalcurrentresearchassessefficacycombinedAtorvastatinhyperlipidemiainducedSD4-week-oldSprague-Dawleymalefednormaltreatedeithervariousdosages3090270mg/kg/daypoanotherComparedonlytreatmentsignificantlyreducedcreatinekinaseaspartateaminotransferaseserummarkersMoreoverreducedfattriglyceridescholesterollow-densitycontrasthigh-densityincreasedco-treatedgroupresultsindicatereducessidealsoanti-obesityeffectThereforeintakesupplementaryhelpfulsolvingmultipleprescriptionmakesusthinkpossibilitysolvedcontiguousobesitysortdiseaseEffectSupplementationStatin-TreatedObeseRatsHyperlipidemiaMyopathy

Similar Articles

Cited By